Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells

Experimental Hematology

Volumn 39, Issue 1, 2011, Pages

  Brassat, Ute ^a   Balabanov, Stefan ^a   Bali, Daniel ^a   Dierlamm, Judith ^a   Braig, Melanie ^a   Hartmann, Ulrike ^b   Sirma, Hüseyin ^c   Günes, Cagatay ^d   Wege, Henning ^a   Fehse, Boris ^a   Gontarewicz, Artur ^a   Dikomey, Ekkehard ^a   Borgmann, Kerstin ^a   Brümmendorf, Tim H ^a,e  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e UNIVERSITY OF AACHEN MEDICAL CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BIBR 1532; PROTEIN P53; TELOMERASE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DICENTRIC CHROMOSOME; DNA DAMAGE; ENZYME INHIBITION; GENOMIC INSTABILITY; LEUKEMIA CELL; PRIORITY JOURNAL; SENESCENCE; TELOMERE;

APOPTOSIS; BLOTTING, WESTERN; GENES, ABL; GENOMIC INSTABILITY; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; TELOMERE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650190882     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.10.001     Document Type: Article

References (35)

1. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079-1082.
2. Moyzis R.K., Buckingham J.M., Cram L.S., et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 1988, 85:6622-6626.
3. Cawthon R.M., Smith K.R., O'Brien E., Sivatchenko A., Kerber R.A. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003, 361:393-395.
4. Harley C.B. Telomere loss: mitotic clock or genetic time bomb?. Mutat Res 1991, 256:271-282.
5. Blackburn E.H. Switching and signaling at the telomere. Cell 2001, 106:661-673.
6. Brummendorf T.H., Balabanov S. Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover. Leukemia 2006, 20:1706-1716.
7. Brummendorf T.H., Holyoake T.L., Rufer N., et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 2000, 95:1883-1890.
8. Koptyra M., Falinski R., Nowicki M.O., et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006, 108:319-327.
9. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci 2002, 27:339-344.
10. Brummendorf T.H., Ersoz I., Hartmann U., et al. Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia. Ann N Y Acad Sci 2003, 996:26-38.
11. Melo J.V., Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7:441-453.
12. Boultwood J., Peniket A., Watkins F., et al. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood 2000, 96:358-361.
13. Ohyashiki K., Ohyashiki J.H., Iwama H., Hayashi S., Shay J.W., Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia 1997, 11:190-194.
14. Graham F.L., van der Eb A.J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973, 52:456-467.
15. Weber K., Bartsch U., Stocking C., Fehse B. A multicolor panel of novel lentiviral 'gene ontology' (LeGO) vectors for functional gene analysis. Mol Ther 2008, 16:698-706.
16. Braig M., Lee S., Loddenkemper C., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665.
17. Benten D., Keller G., Quaas A., et al. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009, 11:934-944.
18. Gontarewicz A., Balabanov S., Keller G., et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008, 111:4355-4364.
19. Baerlocher G.M., Vulto I., de Jong G., Lansdorp P.M. Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc 2006, 1:2365-2376.
20. Rufer N., Brummendorf T.H., Kolvraa S., et al. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med 1999, 190:157-167.
21. Koch K., Wrona A., Dikomey E., Borgmann K. Impact of homologous recombination on individual cellular radiosensitivity. Radiother Oncol 2009, 90:265-272.
22. Bi S., Hughes T., Bungey J., Chase A., de Fabritiis P., Goldman J.M. p53 in chronic myeloid leukemia cell lines. Leukemia 1992, 6:839-842.
23. Chin L., Artandi S.E., Shen Q., et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999, 97:527-538.
24. Damm K., Hemmann U., Garin-Chesa P., et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001, 20:6958-6968.
25. Mueller S., Hartmann U., Mayer F., et al. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors. Invest New Drugs 2007, 25:519-524.
26. Parsch D., Brassat U., Brummendorf T.H., Fellenberg J. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines. Cancer Invest 2008, 26:590-596.
27. Hahn W.C., Stewart S.A., Brooks M.W., et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999, 5:1164-1170.
28. Deng Y., Chan S.S., Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer 2008, 8:450-458.
29. Preto A., Singhrao S.K., Haughton M.F., Kipling D., Wynford-Thomas D., Jones C.J. Telomere erosion triggers growth arrest but not cell death in human cancer cells retaining wild-type p53: implications for antitelomerase therapy. Oncogene 2004, 23:4136-4145.
30. Delhommeau F., Thierry A., Feneux D., et al. Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant. Oncogene 2002, 21:8262-8271.
31. Guo C., Geverd D., Liao R., Hamad N., Counter C.M., Price D.T. Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells. J Urol 2001, 166:694-698.
32. Herbert B., Pitts A.E., Baker S.I., et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci U S A 1999, 96:14276-14281.
33. Röth A., Vercauteren S., Sutherland H.J., Lansdorp P.M. Telomerase is limiting the growth of acute myeloid leukemia cells. Leukemia 2003, 17:2410-2417.
34. Frank O., Rudolph C., Heberlein C., et al. Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood 2004, 104:3543-3549.
35. Calabretta B., Perrotti D. The biology of CML blast crisis. Blood 2004, 103:4010-4022.